Alpha Cognition is trading at $8.84 (up 5.1%) today, driven by the announcement of a new European patent for its Alzheimer’s drug, Zunveyl, which could extend intellectual property protection until 2042. - This patent significantly strengthens Zunveyl's commercial viability in the European market. - Investor optimism is also fueled by the continued commercial launch momentum and strong early-market feedback for the drug.